2026 NPPES data Retina Specialist (Ophthalmology) Physician NPI 1295152379 MD, MBA
Verify on CMS →

MATTHEW POWERS, MD, MBA

Retina Specialist (Ophthalmology) Physician in SANTA ROSA, California. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
459
Medicare Part D claims · 148 beneficiaries · Retina Specialist (Ophthalmology) Physician avg: 558
Generic prescribing
64%
generic claims · 36% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
98.3/100
▲ 15 pts above national avg 83.1 · [object Object]
Industry payments
$34.45
1 payments · CMS Open Payments (Sunshine Act)

What the federal data shows

MATTHEW POWERS, MD, MBA reported a CMS MIPS final score of 98.3/100 — above the 83.1 national average — and filed 459 Medicare Part D claims in 2023.

98.3/100
MIPS score · +15 vs avg
459
Part D claims, 2023
64%
generic prescribing
Likely
board-certified (heuristic)

Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.

MATTHEW POWERS, MD, MBA's MIPS score vs every scored U.S. clinician

CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure

98 Top 11% higher than 89% of 477,587 scored providers

0–10: 8,684 scored providers (2%). Below this entry. 10–20: 3,008 scored providers (1%). Below this entry. 20–30: 3,069 scored providers (1%). Below this entry. 30–40: 2,746 scored providers (1%). Below this entry. 40–50: 2,928 scored providers (1%). Below this entry. 50–60: 5,882 scored providers (1%). Below this entry. 60–70: 13,906 scored providers (3%). Below this entry. 70–80: 118,074 scored providers (25%). Below this entry. 80–90: 129,887 scored providers (27%). Below this entry. 90–100: 189,403 scored providers (40%). This entry sits in this band. This provider 0 100 every MIPS-scored clinician, bucketed by value

Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Merit-based Incentive Payment System (MIPS) · 2023

Board certification likely (heuristic — not verified)

MATTHEW POWERS, MD, MBA practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).

What does the federal data show about MATTHEW POWERS, MD, MBA?

High performer (top quartile)

NPI registry status

Active

Issued 03/26/2014

NPI 1295152379

Primary specialty

Retina Specialist (Ophthalmology) Physician

Niche

913 US NPIs in this specialty

Medicare Part D claims

459 18% vs specialty avg

2023 prescription claims

Specialty avg: 558

MIPS final score

98.3/100 15.200000000000003% pts

Exceptional band

vs 83.1 national avg

Specialty distribution in California

How Retina Specialist (Ophthalmology) Physician compares to other specialties among California providers

California providers

Retina Specialist (Ophthalmology) Physician share within California

1. Retina Specialist (Ophthalmology) Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Retina Specialist (Ophthalmology) Physician share within California

Medicare quality performance — MIPS

MATTHEW POWERS, MD, MBA's 2023 MIPS final score plotted against the Retina Specialist (Ophthalmology) Physician national average

High performer (top quartile)
MIPS Final Score
98.3/100
vs 83.1 national avg · 2023 performance year

MIPS final score (Retina Specialist (Ophthalmology) Physician) — 98.3/100 vs national avg 83.1

0%100%National avg83%98.3%
MIPS final score (Retina Specialist (Ophthalmology) Physician) — 98.3/100 vs national avg 83.1

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

MATTHEW POWERS, MD, MBA appears in the CMS NPPES registry as a Retina Specialist (Ophthalmology) Physician provider holding MD, MBA credentials at 3536 MENDOCINO AVE, SANTA ROSA, CA, 95403, with a listed phone of (720) 848-0000. NPI 1295152379 was issued on 03/26/2014. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what POWERS most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 459 prescription claims written by this provider, covering 148 Medicare beneficiaries and totaling roughly $26K in drug spend, split 36% brand-name and 64% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 98.3/100 for the 2023 performance year, compared with the national average of 83.1.

Retina Specialist (Ophthalmology) Physician is a narrow specialty nationwide, with 913 enrolled providers across 48 states and an average of 558 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

3536 MENDOCINO AVE
SANTA ROSA, CA 95403

Provider Details

NPI 1295152379
Specialty Retina Specialist (Ophthalmology) Physician
Credentials MD, MBA
Gender Male
NPI Issued 03/26/2014

CMS Quality Score (MIPS)

Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.

98.3
Final Score
Avg: 83.1
98
Promoting Interoperability

Reporting: Individual

Industry payments received (2024) — CMS Open Payments transparency data

The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for MATTHEW POWERS, MD, MBA. Source: openpaymentsdata.cms.gov.

Total received

$34

Largest payer

Genentech USA, Inc.

Most common payment type

Food and Beverage

Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.

License & disciplinary context — California MBC 2023 annual report

Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~150K California medical licensees in 2023 — they are NOT specific to MATTHEW POWERS, MD, MBA. To verify MATTHEW POWERS, MD, MBA's current license status, search the MBC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

576
Total board actions, California 2023
Across 556 cases
3.84
Actions per 1,000 licensees
California statewide rate
probation
Most common action type
186 cases

MBC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the California disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Brand vs generic prescribing mix · Above average

MATTHEW POWERS, MD, MBA — brand share 36.0%
Specialty average (est.)

36% brand-name claims vs 64% generic, on 459 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

459
Total Claims
$26K
Total Drug Cost
148
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
669
Total Day Supply
18,436
Brand vs Generic
36% brand / 64% generic
Brand Drug Cost
$17K
Generic Drug Cost
$9K

Patient Demographics

Average Patient Age
74.9 years
Avg HCC Risk Score
1.49
Gender Split
58% female / 42% male
Age Distribution
<65: 14, 65-74: 57, 75-84: 58, 85+: 19

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

What MATTHEW POWERS, MD, MBA prescribes most

Top Medicare Part D drugs by claim count, 2023

claims
Source CMS Medicare Part D Prescriber Public Use File As of 2023
Drug Claims
Prednisolone Acetate
111
Ofloxacin
98
Brimonidine Tartrate
46
Latanoprost
26
Diclofenac Sodium
25
Dorzolamide-Timolol
Dorzolamide Hcl/Timolol Maleat
25
Prolensa
Bromfenac Sodium
23
Difluprednate
18

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Retina Specialist (Ophthalmology) Physician Overview

How MATTHEW POWERS, MD, MBA fits within the Retina Specialist (Ophthalmology) Physician landscape nationally.

913
Retina Specialist (Ophthalmology) Physician Providers in US
48
States with Retina Specialist (Ophthalmology) Physician
558
Avg Claims per Provider

MATTHEW POWERS, MD, MBA's 459 claims are below the specialty average of 558.

Nearby Retina Specialist (Ophthalmology) Physician Providers in California

Other clinicians with the same primary specialty enrolled in California, drawn from the same CMS NPPES roster as POWERS.

Compare Retina Specialist (Ophthalmology) Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is MATTHEW POWERS, MD, MBA's specialty?
MATTHEW POWERS, MD, MBA specializes in Retina Specialist (Ophthalmology) Physician and practices in SANTA ROSA, California. Credentials: MD, MBA.
How much does MATTHEW POWERS, MD, MBA prescribe under Medicare Part D?
In 2023, MATTHEW POWERS, MD, MBA wrote 459 Medicare Part D claims totaling $26K in drug costs for 148 beneficiaries.
What is MATTHEW POWERS, MD, MBA's Medicare quality score?
MATTHEW POWERS, MD, MBA has a CMS MIPS Final Score of 98.3/100. The national average MIPS Final Score is 83.1. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is MATTHEW POWERS, MD, MBA located?
MATTHEW POWERS, MD, MBA is located at 3536 MENDOCINO AVE, SANTA ROSA, CA, 95403. Phone: (720) 848-0000.
What is MATTHEW POWERS, MD, MBA's NPI number?
MATTHEW POWERS, MD, MBA's National Provider Identifier (NPI) is 1295152379, issued on 03/26/2014.
Does MATTHEW POWERS, MD, MBA prescribe more brand-name or generic drugs?
MATTHEW POWERS, MD, MBA's prescribing is 36% brand-name and 64% generic drugs by claim count, with $17K in brand drug costs.
How many Retina Specialist (Ophthalmology) Physician providers are there in the US?
There are 913 Retina Specialist (Ophthalmology) Physician providers across 48 states in the US. The average Retina Specialist (Ophthalmology) Physician provider writes 558 Medicare Part D claims per year.
What drugs does MATTHEW POWERS, MD, MBA prescribe most often?
Based on 2023 Medicare Part D data, MATTHEW POWERS, MD, MBA's most frequently prescribed drugs include Prednisolone Acetate, Ofloxacin, Brimonidine Tartrate. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does MATTHEW POWERS, MD, MBA accept Medicare?
MATTHEW POWERS, MD, MBA appears in CMS Medicare data with 459 Part D claims and 148 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify MATTHEW POWERS, MD, MBA's credentials?
MATTHEW POWERS, MD, MBA's NPI is 1295152379 with credentials MD, MBA. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Quality Performance
CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology